All In Biotech

Drug Trial Radar · NCT05714254

Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers

A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of MEDI0618 in Healthy Male and Female Volunteers

Last checked: Nov 19, 2026Latest source record: Jan 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Dec 12, 2022

Primary completion

Dec 12, 2023

Study completion Dec 12, 2023

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single centre, randomised, double-blind, placebo-controlled, multiple ascending dose study of MEDI0618 in healthy male and female volunteers. Subjects will receive MEDI0618 or placebo administered by intravenous infusion or subcutaneous injection. Safety, tolerability and pharmacokinetics of multiple ascending doses of MEDI0618 will be assessed.

Conditions

  • Chronic Pain

Interventions

  • MEDI0618Drug

    Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.

  • PlaceboDrug

    Four doses of IV placebo or SC placebo administered once every two weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: From Screening, Day 1 to Day 113
  2. Incidence of abnormal vital signsTime frame: From Screening, Day 1 to Day 113
  3. Incidence of abnormal laboratory parametersTime frame: Day -1, Day 15, Day 29, Day 43, Day 57, Day 71, Day 99, Day 113

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.